Nagaraja, Vivek
Spino, Cathie
Bush, Erica
Tsou, Pei-Suen
Domsic, Robyn T.
Lafyatis, Robert
Frech, Tracy
Gordon, Jessica K.
Steen, Virginia D.
Khanna, Dinesh
Funding for this research was provided by:
Bayer Corporation
NIH/NIAMS (K24 AR063120)
Merck Sharp and Dohme (none)
Article History
Received: 10 June 2019
Accepted: 16 August 2019
First Online: 3 September 2019
Ethics approval and consent to participate
: Each site’s institutional review board or ethics committee approved the protocol before the study commenced. The study was conducted in accordance with the principles of the Declaration of Helsinki.
: Not applicable
: Dr. Robyn Domsic has worked as a consultant for paid consultant for Eicos Sciences Inc. and Boehringer-Ingelheim. Dr. Robert Lafyatis has received grant support from PRISM Biolab, Regeneron, Elpidera, and Kiniksa. He has served as a consultant for PRISM Biolab, Merck, Bristol Myers Squibb, Biocon, UCB, Formation, Sanofi, and Genentech/Roche. Dr. Jessica Gordon has received grant support from Corbus Pharmaceuticals and Cumberland Pharmaceuticals. Dr. Dinesh Khanna has served as a consultant for Actelion, Acceleron, BMS, Blade Therapeutics, Boehringer Ingelham, Bayer, ChemomAB, Cytori, Celgene, Curzion, Corbus Pharmaceuticals, CSL Behring, GSK, Genentech, Mitsubishi Tanabe Pharma Development America, Sanofi-Aventis, and UCB. He has stocks in Eicos Sciences, Inc. and has employment with CiviBio Pharma, Inc. He has received grant support from Bristol Myers Squibb, Pfizer, Bayer, and Horizon. The rest of the authors declare that they have no competing interests.